Known targets — ChEMBL curated mechanism
CSF1RFLT1FLT3FLT4KDRPDGFRAPDGFRB
The experimentally established mechanism targets of Linifanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 19/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 16/20 | 1.00 |
| ▸ | CSF1R known ✓ | P07333 | 10/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 10/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 9/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 14/20 | 1.00 |
| ▸ | LYN | P07948 | 7/20 | 1.00 |
| ▸ | SRC | P12931 | 6/20 | 1.00 |
| ▸ | BLK | P51451 | 6/20 | 1.00 |
| ▸ | AURKA | O14965 | 5/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 5/20 | 1.00 |
| ▸ | PLK4 | O00444 | 4/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 4/20 | 1.00 |
| ▸ | MET | P08581 | 4/20 | 1.00 |
| ▸ | PRKACA | P17612 | 4/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 4/20 | 1.00 |
| ▸ | STK3 | Q13188 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linifanib SCHEMBL29375368 | 1.00 | KDR (1.00) | KDRFLT3KITCSF1RFLT4 | |
| Linifanib SCHEMBL1880038 | 0.99 | KDR (0.98) | KDRFLT3KITCSF1RFLT4 | |
| Linifanib SCHEMBL2239943 | 0.97 | KDR (0.94) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL421934 | 0.90 | KDR (0.82) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL420765 | 0.90 | KDR (1.00) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL1662335 | 0.89 | KDR (0.81) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL423705 | 0.89 | KDR (0.80) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL1659063 | 0.89 | KDR (0.79) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL424019 | 0.89 | KDR (0.79) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL6073436 | 0.89 | KDR (0.79) | KDRFLT3KITCSF1RFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4138 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260142007-A1 | DIGITAL THERAPEUTICS AND COMBINATION THERAPY FOR THE TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR (TGCT) | REMEPY HEALTH LTD (IL) | 2026-05-21 | — | — | US | claimed |
| EP-4735120-A2 | CHEMICALLY INDUCED REPROGRAMMING TO REVERSE AGING | President and Fellows of Harvard College (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4729519-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| EP-4719387-A2 | COMPLEMENT ANTIBODY-DRUG CONJUGATES | ADS Therapeutics LLC (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260076943-A1 | METHOD FOR IMPROVING SKELETAL HEALTH | UNIV INDIANA TRUSTEES (US) | 2026-03-19 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| WO-2026041394-A1 | A CSF1R INHIBITOR AND A BONE MARROW CELL POPULATION FOR THE REPLACEMENT OF MICROGLIA AND CENTRAL NERVOUS SYSTEM-ASSOCIATED MACROPHAGES IN CENTRAL NERVOUS SYSTEM DISEASES | Albert-Ludwigs-Universität Freiburg, Körperschaft des öffentlichen Rechts (DE) | 2026-02-26 | — | — | WO | claimed |
| US-20260028587-A1 | COMPOSITIONS AND METHODS FOR MICROGLIA REPLACEMENT THERAPY | NOVOGLIA, INC. | 2026-01-29 | — | — | US | claimed |
| US-12522873-B2 | ALK and NTRK1 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2026-01-13 | — | — | US | claimed |
| US-12491183-B2 | Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization | ADS THERAPEUTICS LLC (US) | 2025-12-09 | — | — | US | claimed |
| US-20070148225-A1 | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE | ALCON, INC. (US) | 2007-06-28 | — | — | US | claimed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | claimed |
| US-20070104780-A1 | Formulation comprising a drug of low water solubility and method of use thereof | ABBVIE INC. | 2007-05-10 | — | — | US | claimed |
| WO-2006091801-A2 | METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS | ALCON, INC. (CH) | 2006-08-31 | — | — | WO | claimed |
| US-20060189608-A1 | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors | ALCON, INC. | 2006-08-24 | — | — | US | claimed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | claimed |
| EP-1638941-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-03-29 | — | — | EP | claimed |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. | 2005-01-27 | — | — | US | claimed |
| WO-2004113304-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABBOTT LABORATORIES | 2004-11-25 | — | — | US | claimed |